Press release
Oxipit and Parasmed partnership to extend CXR AI product distribution in Eastern Africa
Before Oxipit software is made available in the Kenyan market, Parasmed will partner with local high-level medical institutions to evaluate its performance in the local healthcare setting.
“We are starting off with this approach to showcase the software performance utilizing local real-world clinical data, as well as to demonstrate AI workflow for local medical institutions” - notes CEO of Parasmed Prof. Osmo Tervonen.
A number of AI solutions were evaluated before entering the partnership. In the words of Prof. Osmo Tervonen, Oxipit software was chosen for its diagnostic performance. In addition, Oxipit software covers the widest scope of radiological respiratory findings, which could bring a significant boost to radiologists in the region.
“Furthermore, Oxipit is present at every step of journey with its distributor partners - research, training, deployment and support” - adds Prof. Tervonen.
As well as other regions in the developing world, Eastern Africa suffers from the lack of radiologists and insufficient imaging technology. There are slightly more than 200 practicing radiologists in Kenya - a puny number considering the overall population.
“With economic and population growth, AI diagnostic tools are the best bet to bridge the gap of healthcare quality in the developing countries” - says CEO of Oxipit Gediminas Peksys.
Oxipit chest X-ray diagnostic software provides preliminary reports for 75 radiological findings, significantly reducing the workload of radiologists in day-to-day operations. Further developments of the software - including autonomous healthy patient reports - will produce even more cost and resource savings.
“AI diagnostics are already present in day-to-day medical practice. Yet now we are at an exciting stage, where AI diagnostics are moving towards more autonomous operations. The developing countries will benefit the most from this AI evolution, enabling a developed-world level of patient care without the associated developed-world healthcare costs” - adds Mr Peksys.
COMPANY CONTACT
Saulėtekio al. 15-1, LT-10224 Vilnius, Lithuania
Mantas Miksys
Marketing Partner
info@oxipit.ai
ABOUT OXIPIT (www.oxipit.ai)
Oxipit is a computer vision software startup specialized in medical imaging. With a team of award-winning data scientists and medical doctors, the company aims to introduce innovative Artificial Intelligence/Deep Learning breakthroughs to everyday clinical practice. Oxipit is the authors of CE certified multi-award winning ChestEye radiology imaging suite.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Oxipit and Parasmed partnership to extend CXR AI product distribution in Eastern Africa here
News-ID: 2223931 • Views: …
More Releases from Oxipit
Oxipit Partners With CARPL To Increase Global Reach Of AI Diagnostic Products
At the European Congress of Radiology in Vienna Oxipit announced that its diagnostic AI solutions will be available on the CARPL platform. CARPL platform users will have access to the full Oxipit AI product portfolio: ChestLink for healthy patient report automation, Quality - for real-time quality assurance and ChestEye - for preliminary reports. The move further builds on Oxipit strategy to increase global reach of company's products.
"CARPL is our…
Oxipit Secures Brazilian ANVISA Clearance for ChestEye AI Suite
The regulatory approval paves the way for ChestEye deployments in the Brazilian market. The application is already cleared for use in Europe and Australia. The Brazilian Health Regulatory Agency's approval is one of Oxipit steps to increase global reach for company products.
"With many future-focused healthcare organizations, LatAm market shows tremendous potential for healthcare AI applications. Oxipit products have already shown strong market traction in the region. The ANVISA certification…
Oxipit Closes $4.9M Funding Round To Advance AI Autonomy in Medical Imaging
AI medical imaging company Oxipit closed a $4.9M funding round led by Taiwania Capital and Practica Capital. Angel investors also participated in this round. The funding will help Oxipit advance its development of autonomous AI medical imaging applications and support market expansion into new geographic regions, with particular focus on the United Kingdom.
"2022 was a breakthrough year for the Oxipit team. In spring we introduced ChestLink - the first fully…
Oxipit Introduces Quality Assurance for MSK, MG, and CT Modalities
AI medical imaging company Oxipit expanded its Quality product suite with quality assurance support for musculoskeletal X-rays, mammography images and lung CT scans. Previously supporting only chest X-rays, the upgraded Quality suite aims to answer all imaging department quality assurance needs with a single product. The updated Quality product will be showcased at RSNA 2022 annual meeting later this month.
Oxipit Quality employs AI as the second reader for quality assurance.…
